APA (7th ed.) Citation

Mowery, Y. M., Ballman, K. V., Hong, A. M., Schuetze, S. M., Wagner, A. J., Monga, V., . . . Kirsch, D. G. (2024). Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): An open-label, randomised clinical trial. The Lancet (British edition), 404(10467), 2053-2064. https://doi.org/10.1016/S0140-6736(24)01812-9

Chicago Style (17th ed.) Citation

Mowery, Yvonne M., et al. "Safety and Efficacy of Pembrolizumab, Radiation Therapy, and Surgery Versus Radiation Therapy and Surgery for Stage III Soft Tissue Sarcoma of the Extremity (SU2C-SARC032): An Open-label, Randomised Clinical Trial." The Lancet (British Edition) 404, no. 10467 (2024): 2053-2064. https://doi.org/10.1016/S0140-6736(24)01812-9.

MLA (9th ed.) Citation

Mowery, Yvonne M., et al. "Safety and Efficacy of Pembrolizumab, Radiation Therapy, and Surgery Versus Radiation Therapy and Surgery for Stage III Soft Tissue Sarcoma of the Extremity (SU2C-SARC032): An Open-label, Randomised Clinical Trial." The Lancet (British Edition), vol. 404, no. 10467, 2024, pp. 2053-2064, https://doi.org/10.1016/S0140-6736(24)01812-9.